The global interventional oncology market size was valued at USD 2.68 billion in 2024 and is projected to grow at a CAGR of 8.55% from 2025 to 2030. This growth can be attributed to the increasing prevalence of cancer, increasing technological advancements in minimally invasive procedures, growing geriatric population, rising focus on early cancer detection, and increasing public and private investments in the field of interventional oncology. There is a significant rise in the number of cancer cases globally, increasing the need for advanced solutions facilitating better cancer care. According to the WHO, in 2022, approximately 20 million new cancer cases and 9.7 million deaths occurred. By 2050, cases are projected to rise to over 35 million, marking a 77% increase in the global cancer burden.
Interventional oncology, with its array of minimally invasive techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cryoablation, offers significant advantages over traditional surgery, including reduced recovery times and lower complication rates. As the global cancer burden continues to rise, the adoption of these advanced interventional techniques is expected to accelerate, driven by their ability to improve patient outcomes and quality of life.
The rising global incidence of cancer is largely attributed to increasing tobacco use, unhealthy diets, alcohol consumption, air pollution, and physical inactivity. This surge in cancer cases poses a significant challenge for healthcare systems, spurring the development of advanced solutions that offer better results and outcomes. Interventional oncology, which provides a minimally invasive alternative to traditional cancer treatments such as surgery, radiation, and chemotherapy, has become increasingly popular. Its advantages in terms of reduced patient trauma and quicker recovery times are key factors driving market growth.
These staggering statistics highlight the urgent need for effective cancer treatments. Interventional oncology, with its array of minimally invasive techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cryoablation, offers significant advantages over traditional surgery, including reduced recovery times and lower complication rates. As the global cancer burden continues to rise, the adoption of these advanced interventional techniques is expected to accelerate, driven by their ability to improve patient outcomes and quality of life.
Companies in the industry are actively pursuing various strategies to develop advanced solutions aimed at improving patient treatment and care. For example, in April 2021, Terumo launched its global therapeutic interventional oncology team to achieve excellence in interventional oncology solutions, with the goal of enhancing patient quality of life and survival rates. Such initiatives are expected to spur the development of innovative solutions, increasing the adoption of interventional oncology and driving market growth.
Moreover, increased efforts to develop advanced solutions have led to significant investments from both government and private organizations. In June 2023, Royal Philips announced that the Philips-coordinated IMAGIO consortium of clinical partners received a grant of approximately $25.97 million. This funding is intended to support research on minimally invasive cancer treatments, with a focus on liver cancer, lung cancer, and soft tissue sarcomas. Such investments are crucial for advancing interventional oncology technologies and improving patient outcomes.
This product will be delivered within 2 business days.
Interventional oncology, with its array of minimally invasive techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cryoablation, offers significant advantages over traditional surgery, including reduced recovery times and lower complication rates. As the global cancer burden continues to rise, the adoption of these advanced interventional techniques is expected to accelerate, driven by their ability to improve patient outcomes and quality of life.
The rising global incidence of cancer is largely attributed to increasing tobacco use, unhealthy diets, alcohol consumption, air pollution, and physical inactivity. This surge in cancer cases poses a significant challenge for healthcare systems, spurring the development of advanced solutions that offer better results and outcomes. Interventional oncology, which provides a minimally invasive alternative to traditional cancer treatments such as surgery, radiation, and chemotherapy, has become increasingly popular. Its advantages in terms of reduced patient trauma and quicker recovery times are key factors driving market growth.
These staggering statistics highlight the urgent need for effective cancer treatments. Interventional oncology, with its array of minimally invasive techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cryoablation, offers significant advantages over traditional surgery, including reduced recovery times and lower complication rates. As the global cancer burden continues to rise, the adoption of these advanced interventional techniques is expected to accelerate, driven by their ability to improve patient outcomes and quality of life.
Companies in the industry are actively pursuing various strategies to develop advanced solutions aimed at improving patient treatment and care. For example, in April 2021, Terumo launched its global therapeutic interventional oncology team to achieve excellence in interventional oncology solutions, with the goal of enhancing patient quality of life and survival rates. Such initiatives are expected to spur the development of innovative solutions, increasing the adoption of interventional oncology and driving market growth.
Moreover, increased efforts to develop advanced solutions have led to significant investments from both government and private organizations. In June 2023, Royal Philips announced that the Philips-coordinated IMAGIO consortium of clinical partners received a grant of approximately $25.97 million. This funding is intended to support research on minimally invasive cancer treatments, with a focus on liver cancer, lung cancer, and soft tissue sarcomas. Such investments are crucial for advancing interventional oncology technologies and improving patient outcomes.
Global Interventional Oncology Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the global interventional oncology market report based on techniques, procedures, applications, end-use, and region.Techniques Outlook (Revenue, USD Million, 2018 - 2030)
- Ablation Therapies
- Radiofrequency Ablation (RFA)
- Microwave Ablation (MWA)
- Cryoablation
- Laser Ablation
- Irreversible Electroporation (IRE)
- Embolization Therapies
- Transarterial Chemoembolization (TACE)
- Transarterial Radioembolization (TARE)
- Biopsy Techniques
- Core Needle Biopsy
- Fine Needle Aspiration (FNA)
- Targeted Therapy Delivery Systems
- Drug-Eluting Beads
- Radioembolization
- Drug-Eluting Stents
- Injectable Hydrogels and Nanoparticles
- Other Targeted Therapy Systems
- Image-Guided Procedures
- Ultrasound Guidance
- CT Scan Guidance
- MRI Guidance
- Fluoroscopy Guidance
Procedure Outlook (Revenue, USD Million, 2018 - 2030)
- Tumor Ablation
- Tumor Biopsy
- Vascular Interventions
- Palliative Care
Application Outlook (Revenue, USD Million, 2018 - 2030)
- Liver Cancer
- Lung Cancer
- Kidney Cancer
- Prostate Cancer
- Breast Cancer
- Other Cancer
End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Specialty Clinics
- Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This Report Addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Interventional Oncology Market Variables, Trends & Scope
Chapter 4. Interventional Oncology Market: Technique Estimates & Trend Analysis
Chapter 5. Interventional Oncology Market: Procedures Estimates & Trend Analysis
Chapter 6. Interventional Oncology Materials Market: Applications Estimates & Trend Analysis
Chapter 7. Interventional Oncology Market: End-use Estimates & Trend Analysis
Chapter 8. Interventional Oncology Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Medtronic plc
- Boston Scientific Corporation
- Johnson & Johnson (Ethicon)
- Teleflex Incorporated
- Cook Medical
- AngioDynamics Inc.
- Stryker Corporation
- Profound Medical
- Terumo Corporation
- Siemens Healthineers
- View a comprehensive list of com
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 210 |
| Published | March 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.68 Billion |
| Forecasted Market Value ( USD | $ 4.38 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
